Abstract:BackgroundColorectal cancer (CRC) is an important death-related disease in the world and new therapeutic strategies are urgently needed to reduce mortality. Several studies have demonstrated that emodin, the main ingredient of Rheum palmatum, fights cancer but its potential anti-tumor effect on CRC is still unknown.PurposeThe present study is aimed to explore the potential anti-tumor effects of emodin against CRC and the underlying molecular mechanism.MethodsCRC-related datasets were screened according to filter criteria in the GEO database and TCGA database. By using screened differentially expressed genes, GO, KEGG and survival analysis were carried out. The expressions of ACSL4, VEGFR1, and VEGFR2 were examined by immunohistochemistry and western blot. Then, pcDNA-ACSL4, pcDNA-VEGFR1, and pcDNA-VEGFR2 were used to overexpress ACSL4, VEGFR1, and VEGFR2, while ACSL4 siRNA was used to silence ACSL4 expression in HCT116 cells. CCK-8 assay and transwell migration assay were used to detect the cell proliferation and invasion. A docking simulation assay and an MST assay were performed to explore the potential mode of emodin binding to ACSL4. The HCT116 cells and CRC mouse model were established to investigate the effects of emodin on CRC.ResultsThe ACSL4, VEGFR1, and VEGFR2 expression were upregulated in CRC tissues and ACSL4 was associated with a shorter survival time in CRC patients. ACSL4 downregulation reduced cell proliferation and invasion, while ACSL4 exhibited a positive correlation with the levels of VEGFR1, VEGFR2, and VEGF. In HCT116 cells, emodin reduced cell proliferation and invasion by inhibiting ACSL4, VEGFR1, and VEGFR2 expression and VEGF secretion. Docking simulation and MST assay confirmed that emodin can directly bind to ACSL4 target. Moreover, ACSL4 overexpression abolished the inhibitory effect of emodin on VEGF secretion and VEGFR1 and VEGFR2 expression, but VEGFR1 and VEGFR2 overexpression did not affect the inhibitory effect of emodin on ACSL4 expression and VEGF secretion. Furthermore, emodin reduced the mortality and tumorigenesis of CRC mice and reduced ACSL4, VEGFR1, VEGFR2 expression, and VEGF content.ConclusionOur findings indicate that emodin inhibits proliferation and invasion of CRC cells and reduces VEGF secretion and VEGFR1 and VEGFR2 expression by inhibiting ACSL4. This emodin-induced pathway offers insights into the molecular mechanism of its antitumor effect and provides a potential therapeutic strategy for CRC.

Anti‐tumor efficacy of emodin on colorectal cancer cells via targeting lncRNA HLA complex P5

25-hydroxycholesterol Regulates Migration, Invasion and EMT of Colorectal Cancer through miR-92a-3p/ACAA1/NF-κB Pathway

Anticancer Effects of Emodin on HepG2 Cell: Evidence from Bioinformatic Analysis

ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin

Anti-Cancer Effects Of Emodin On Hepg2 Cells As Revealed By H-1 Nmr Based Metabolic Profiling

Antitumor Effects of Emodin on LS1034 Human Colon Cancer Cells in Vitro and in Vivo: Roles of Apoptotic Cell Death and LS1034 Tumor Xenografts Model

Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression

Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMAD5 axis in gastric cancer cells

Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin

Long Intergenic Non-Coding RNA LINC00485 Exerts Tumor-Suppressive Activity by Regulating Mir-581/Edem1 Axis in Colorectal Cancer.

Anticancer potential of emodin

Emodin Suppresses the Migration and Invasion of Melanoma Cells

Inhibition of hERG by ESEE suppresses the progression of colorectal cancer

Down-regulation of aquaporin 5-mediated epithelial-mesenchymal transition and anti-metastatic effect by natural product Cairicoside E in colorectal cancer.

Emodin Inhibits the Growth of Hepatoma Cells: Finding the Common Anti-Cancer Pathway Using Huh7, Hep3B, and HepG2 Cells.

Effect of emodin combined with cisplatin on the invasion and migration of HepG2 hepatoma cells

Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway

Emodin Regulates the Autophagy Via the Mir-371A-5p/pten Axis to Inhibit Hepatic Malignancy

Emodin Promotes Apoptosis of Human Endometrial Cancer Through Regulating the MAPK and PI3K/ AKT Pathways

Synergic effects and possible mechanism of emodin and stilbene glycosides on colorectal cancer

Antitumor Effects and Mechanism of Novel Emodin Rhamnoside Derivatives against Human Cancer Cells In Vitro